Core Insights - Aligos Therapeutics, Inc. has appointed Laura Kavanaugh as Vice President, Head of Legal, effective immediately, bringing over 25 years of experience in the biotechnology and pharmaceutical industries [1][2][3] Company Overview - Aligos Therapeutics is a clinical stage biotechnology company focused on developing therapies for liver and viral diseases, aiming to improve patient outcomes [3] - The company is dedicated to addressing high unmet medical needs, including chronic hepatitis B virus infection and metabolic dysfunction-associated steatohepatitis (MASH) [3] Leadership Appointment - Laura Kavanaugh's previous roles include Vice President, Corporate Law & Privacy Officer at Codexis and independent legal consultant for various biotech firms [2] - Kavanaugh's expertise is expected to enhance Aligos' legal oversight and support its mission [2]

Core Insights - Aligos Therapeutics, Inc. announced positive data from eight presentations at the EASL Congress 2025, highlighting advancements in therapies for liver and viral diseases [1][2] Group 1: ALG-000184 for Chronic Hepatitis B - The 96-week data from the monotherapy cohort receiving 300 mg ALG-000184 showed that all subjects in both HBeAg+ and HBeAg- cohorts achieved HBV DNA viral suppression below the lower limit of quantification (LLOQ) [2][3] - In HBeAg+ subjects, 60% achieved HBV DNA < LLOQ at Week 48, which increased to 100% at Week 96, with HBV DNA levels declining to < LLOQ in 5 of 9 subjects [3] - All HBeAg- subjects (100%) experienced rapid HBV DNA suppression by Week 24, maintaining suppression for up to 96 weeks [4] - No viral breakthrough was observed in any subjects receiving ALG-000184 for up to 96 weeks, and no known resistant mutations were identified [5] Group 2: ALG-055009 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) - ALG-055009 demonstrated significant reductions in liver fat content, with placebo-adjusted median relative reductions up to 46.2% at Week 12 [8] - The treatment was well-tolerated, with gastrointestinal-related adverse events similar to placebo [8] - Statistically significant improvements in atherogenic lipids were observed, indicating potential cardiovascular benefits alongside liver fat reduction [9][10] Group 3: Presentation Details - Key presentations included data on ALG-000184's antiviral effects and safety, as well as ALG-055009's impact on liver fat and lipid profiles [10][11][12] - Notable presenters included experts from the University of Hong Kong and Southern Medical University, showcasing the clinical significance of the findings [10][11] Group 4: Company Overview - Aligos Therapeutics is focused on developing best-in-class therapies for liver and viral diseases, leveraging its R&D expertise to address high unmet medical needs [15]

Company Performance - Aligos Therapeutics reported a quarterly loss of $2.11 per share, which was better than the Zacks Consensus Estimate of a loss of $2.80, and an improvement from a loss of $5.50 per share a year ago, indicating a 24.64% earnings surprise [1] - The company posted revenues of $0.31 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 68.90%, and down from $0.99 million in the same quarter last year [2] - Over the last four quarters, Aligos Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - Aligos Therapeutics shares have declined approximately 87.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$2.74 on $1 million in revenues, and for the current fiscal year, it is -$8.66 on $39.5 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Aligos Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aligos Therapeutics' stock performance [5][6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4724808 (State or other jurisd ...

Financial Performance - Net income for Q1 2025 was $43.1 million, with a basic net income per share of $5.12, compared to a net loss of $34.9 million in Q1 2024[6]. - The change in fair value of common warrants resulted in income of $61.5 million for Q1 2025, compared to a loss of $14.4 million in Q1 2024[11]. - Cash, cash equivalents, and investments totaled $137.9 million as of March 31, 2025, up from $56.9 million as of December 31, 2024, providing funding into the second half of 2026[5]. - Total liabilities decreased to $34.3 million as of March 31, 2025, from $99.1 million as of December 31, 2024[18]. Research and Development - Aligos raised over $100 million to initiate a Phase 2 study of ALG-000184 for chronic hepatitis B virus infection, with dosing expected to begin by mid-2025[2]. - Research and development expenses decreased to $14.5 million in Q1 2025 from $16.4 million in Q1 2024, primarily due to reduced clinical trial costs[7]. - ALG-000184 demonstrated 100% sustained HBV DNA suppression in HBeAg subjects after 48 weeks of treatment[3]. - The Phase 2 B-SUPREME study for ALG-000184 is expected to enroll approximately 200 untreated adult subjects with chronic HBV infection[3]. - ALG-055009 showed statistically significant liver fat reductions of up to 46.2% at week 12 in MASH patients, with 70% of subjects achieving a ≥30% relative reduction[10]. Operating Expenses - General and administrative expenses fell to $5.1 million in Q1 2025 from $6.7 million in Q1 2024, attributed to lower third-party expenses[8].

Core Insights - Aligos Therapeutics is advancing its clinical development plans for therapies targeting liver and viral diseases, having raised over $100 million for its Phase 2 study of ALG-000184 in chronic hepatitis B virus infection [2][3] - The company reported significant financial progress, with a net income of $43.1 million for Q1 2025, a substantial improvement from a net loss of $34.9 million in Q1 2024 [7][10] Recent Business Progress - Aligos is on track to begin dosing for the Phase 2 study of ALG-000184 by mid-2025, following positive FDA correspondence [2] - Data presented at the APASL meeting indicated that ALG-000184 has the potential to be a first-line treatment for chronic HBV infection, with a well-tolerated profile and promising antiviral activity [5][12] - The Phase 2 B-SUPREME study will evaluate ALG-000184 against tenofovir disoproxil fumarate in approximately 200 untreated adult subjects with chronic HBV infection [5] Pipeline Updates - ALG-000184 is positioned as a potential first-/best-in-class small molecule for chronic hepatitis B virus infection [3] - ALG-055009, a THR-β agonist for metabolic dysfunction-associated steatohepatitis (MASH), has shown best-in-class potential, with significant reductions in liver fat observed in clinical trials [4][12] - The company is in discussions for potential partnerships regarding ALG-055009 with multinational pharmaceutical companies [2] Financial Results for Q1 2025 - Cash, cash equivalents, and investments totaled $137.9 million as of March 31, 2025, compared to $56.9 million at the end of 2024, providing sufficient funding into the second half of 2026 [6] - Research and development expenses decreased to $14.5 million from $16.4 million year-over-year, primarily due to reduced third-party clinical trial expenses [8] - General and administrative expenses also decreased to $5.1 million from $6.7 million, reflecting lower third-party costs [9]

Core Viewpoint - Aligos Therapeutics, Inc. is set to report its first quarter 2025 financial results on May 6, 2025, before the U.S. financial markets open, indicating ongoing developments in its clinical-stage biotechnology efforts focused on liver and viral diseases [1]. Company Overview - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to improving patient outcomes through the development of best-in-class therapies for liver and viral diseases [2]. - The company utilizes a science-driven approach and extensive R&D expertise to advance its pipeline of therapeutics targeting high unmet medical needs, including chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses [2].

Core Viewpoint - Aligos Therapeutics, Inc. has announced that eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, highlighting its focus on innovative therapies for liver and viral diseases [1]. Group 1: Abstracts on Chronic Hepatitis B Virus (HBV) - Abstract 861 discusses the monotherapy with the novel capsid assembly modulator ALG-000184, showing profound and sustained HBV DNA suppression in untreated subjects over 96 weeks [2]. - Abstract 856 presents the safety and antiviral effect of oral daily 300 mg ALG-000184 in combination with Entecavir for untreated HBeAg-positive subjects, also over 96 weeks [3]. - Abstract 1924 reveals a high barrier of resistance to ALG-000184 based on viral kinetics and sequence analysis from a phase I monotherapy study [3]. Group 2: Abstracts on Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Abstract 302 highlights that ALG-055009, a novel thyroid hormone receptor beta agonist, significantly reduces atherogenic lipids/lipoproteins in patients with presumed MASH in the Phase 2a HERALD study [4]. - Abstract 2185 indicates robust reductions in liver fat at Week 12 across subgroups, including GLP-1 receptor agonist users in non-cirrhotic MASH patients [4]. - Abstract 2152 discusses population pharmacokinetic/pharmacodynamic modeling of ALG-055009, showing a statistically significant correlation between exposure and key efficacy endpoints [5]. Group 3: Preclinical Research - Abstract 2105 presents next-generation hepatitis B virus antisense oligonucleotides with significantly improved properties compared to current clinical candidates [6]. Company Overview - Aligos Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing best-in-class therapies for liver and viral diseases, leveraging its R&D expertise to address high unmet medical needs [6].

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China. “We are pleased to present preliminary da ...

Company Performance - Aligos Therapeutics reported a quarterly loss of $3.41 per share, significantly worse than the Zacks Consensus Estimate of a loss of $1.91, representing an earnings surprise of -78.53% [1] - The company's revenues for the quarter ended December 2024 were $0.63 million, missing the Zacks Consensus Estimate by 51.62%, and down from $2.68 million a year ago [2] - Over the last four quarters, Aligos Therapeutics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Movement and Outlook - Aligos Therapeutics shares have declined approximately 67.5% since the beginning of the year, contrasting with the S&P 500's decline of -1.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is -$2.04 on $1 million in revenues, and for the current fiscal year, it is -$8.94 on $4 million in revenues [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Aligos Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aligos Therapeutics' stock performance [5][6]